How To Pay For The New Wave Of Gene Therapies
New models of paying for gene therapies will emerge as more of these innovative treatments, particularly outside the rare disease and oncology spaces, hit the market.
You may also be interested in...
NICE’s rapid decision to recommend funding in England and Wales for Novartis’s gene therapy Luxturna is a result of what the company calls its "collaborative and transparent" approach to negotiations over the health technology assessment of innovative new therapies. Novartis explains why this appraisal process was completed so quickly.
The ABPI, which represents the R&D-based pharmaceutical industry in the UK, says the proposed increase in the statutory scheme rebate sends "the worst possible signal" to global investors and boardrooms.
The German pharmaceutical industry is calling for “directional correction” to the way implementation of the EU’s Health Technology Assessment Regulation is being developed.